Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2


Oral and Poster Abstracts Oral 613. Acute Myeloid Leukemia: Clinical and Epidemiological: Practice-changing studies Acute Myeloid Malignancies, Non-Biological, AML, Clinical Research, Clinically Relevant, Diseases, Therapies, Myeloid Malignancies Sangeetha Venugopal, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Courtney D. DiNardo, MD, MSCE,...

  • 123456 Profile photo of Madelyn

    This is a retrospective analysis of patients with secondary AML with prior HMA exposure treated with either AZA/VEN, low intensity treatment or higher intensity treatment. Pateints treated with high intensity treatment were a median 7 years younger. Cr/CRi rate was 26% adn ORR was 34% in the entire cohort, with similar rates between intensive and low intensity chemotherapy. HMA+Ven was associated with higher CR/CRi rates (39% vs 25%) and ORR (54% vs 33%). Similarly, OS was superior for the patients treated with HMA+Ven (median OS 5.8 months).